Semiconductor Equipment Surges, Innovative Drug Concept Falls: Logic and Outlook Behind Market Divergence
Introduction
Recently, the A-share market has shown significant structural divergence. On one hand, the semiconductor equipment sector performed brightly under capital pursuit, with the China Merchants Semiconductor Equipment ETF (561980) surging 3.12% on heavy volume, becoming a focal point. On the other hand, the innovative drug concept collectively fell, with stocks like Lianhuan Pharmaceutical and Anglikang even hitting limit-down. This stark contrast not only reflects the current market sentiment divergence but also reveals the deep-seated game among different industry cycles, policy environments, and capital preferences. This article analyzes this market phenomenon from dimensions such as sector performance, driving factors, risk challenges, and future trends.
1. Semiconductor Equipment Sector: Dual Drive from Demand Recovery and Technological Breakthroughs
1.1 Sector Performance and Market Sentiment
The heavy-volume surge of the China Merchants Semiconductor Equipment ETF (561980) is not an isolated event. Recently, the semiconductor equipment sector as a whole has seen net capital inflows, with many stocks hitting new stage highs. Behind this trend is the market's optimistic expectation of a recovery in the semiconductor industry chain. Technically, the ETF broke through its previous consolidation range on heavy volume, indicating strong willingness of main capital to intervene; fundamentally, global semiconductor equipment shipments have shown signs of stabilizing after consecutive declines.
1.2 Driving Factor Analysis
(1) Global semiconductor cycle inflection point approaching
The semiconductor industry has obvious cyclical characteristics. Against the backdrop of gradual global economic recovery, explosive demand for AI large model computing power, and accelerated intelligence of new energy vehicles, semiconductor equipment, as the "water seller" in the upstream of the industry chain, first benefits from capital expenditure expansion. According to SEMI data, global semiconductor equipment sales in 2024 are expected to grow over 5% year-on-year, with China's growth rate likely higher.
(2) Accelerated domestic substitution process
The deepening technology competition between China and the US, with escalating US export controls on semiconductor to China, forces domestic wafer fabs to accelerate equipment localization. Leading domestic equipment companies like Beifang Huachuang and Zhongwei Company have made breakthroughs in key processes such as etching, thin film deposition, and cleaning, with steadily increasing market shares. At the policy level, the establishment of Phase III of the National Big Fund is imminent, focusing on equipment and materials, further strengthening market expectations.
(3) Clear expansion pace of domestic wafer fabs
Major domestic wafer fabs like SMIC and Hua Hong Semiconductor continue to expand capacity, while storage IDM enterprises such as Yangtze Memory and Hefei Changxin are also pushing mass production of advanced processes. Equipment procurement demand is shifting from destocking to restocking, driving order growth for related companies. The heavy positions of the China Merchants Semiconductor Equipment ETF are mostly direct beneficiaries of this expansion cycle.
2. Innovative Drug Concept: Collective Decline Under Valuation Digestion and Policy Pressure
2.1 Sector Performance and Market Sentiment
In stark contrast to the strength of semiconductor equipment, the innovative drug sector has recently suffered a heavy blow. Stocks like Lianhuan Pharmaceutical and Anglikang hit limit-down, and the overall sector index fell the most. This is not a denial of the long-term value of innovative drugs, but a concentrated release of multiple short-term negative factors. Previously, the innovative drug sector had risen for half a year, with valuations at historically high percentiles, creating a need for correction.
2.2 In-depth Analysis of Reasons for the Decline
(1) Increased pressure from medical insurance negotiations
The adjustment of the 2024 National Medical Insurance Catalog has been launched, intensifying market concerns about price reductions after innovative drugs are included in medical insurance. Especially under the main tone of "cost control," some companies face a choice of "exchanging price for volume," compressing short-term profit margins. The large declines in stocks like Lianhuan Pharmaceutical and Anglikang are directly related to market expectations of price pressure on their core varieties.
(2) Rising uncertainty of R&D pipelines
Innovative drug R&D is characterized by high investment, high risk, and long cycles. Recently, some companies' core R&D projects have faced clinical data falling short of expectations or approval delays, raising doubts about pipeline success rates. Combined with repeated fluctuations in expectations of Fed rate cuts, biopharmaceutical investment and financing enthusiasm has cooled, weighing on related company valuations.
(3) Capital rotation and style switching
Market capital is rotating from high-valuation growth sectors to technology manufacturing sectors with stronger certainty. The surge in semiconductor equipment ETF partly comes from funds withdrawn from the pharmaceutical sector. This "seesaw" effect is particularly evident when market sentiment is cautious. In addition, northbound capital's overall allocation to the pharmaceutical sector has recently declined, exacerbating adjustment pressure.
3. Deep Logic Behind Industry Divergence
3.1 Different Industry Cycle Positions
Semiconductor equipment is in the early stage of an upward cycle, while innovative drugs are in a period of inventory digestion and policy digestion. The former benefits from the double dividend of global capital expenditure recovery and domestic substitution, while the latter is constrained by medical insurance cost control and R&D uncertainty. This cycle mismatch is the fundamental reason for the divergent performance of sectors.
3.2 Differences in Policy Environment
Semiconductor equipment is supported by national strategies, with continuous favorable policies, and external sanctions actually accelerate domestic substitution, forming a "reverse catalyst." In contrast, the policy environment for innovative drugs is more complex: it needs to encourage innovation while controlling medical costs. In 2024, the General Office of the State Council's "Key Tasks for Deepening Medical and Health System Reform in 2024" clearly requires promoting the normalization of drug centralized procurement, putting pressure on both generic and innovative drugs.
3.3 Market Expectations and Valuation Matching
The semiconductor equipment sector, after previous adjustments, is valued in a reasonable range with high earnings growth certainty, attracting institutional funds with lower risk appetite. The innovative drug sector, due to large previous gains, had valuations that overdrew some future expectations; once negative news appears, short-term selling pressure is significant.
4. Future Outlook and Investment Strategies
4.1 Semiconductor Equipment: Focus on Localization Rate Improvement and Earnings Fulfillment
Although short-term gains are large, the long-term trend for semiconductor equipment remains positive. Investors should focus on: first, leading companies with high order visibility, such as Beifang Huachuang and Zhongwei Company; second, growth stocks that have achieved breakthroughs in sub-sectors, such as Tuojing Technology and Shengmei Shanghai. At the same time, it is necessary to note that the global semiconductor cycle recovery may fall short of expectations, along with repeated geopolitical risks.
4.2 Innovative Drugs: Patiently Wait for Valuation Return and Policy Inflection Point
The long-term value of the innovative drug sector cannot be ignored, but short-term adjustments are not yet over. Investors can focus on: first, companies with differentiated innovative pipelines and controllable impacts from medical insurance negotiations; second, companies with stable cash flow and high R&D efficiency. When the sector valuation returns to historical lows and signs of marginal policy improvement appear, it will be a good time to position.
4.3 Balanced Allocation, Seize Structural Opportunities
In the current market environment, it is recommended to adopt a balanced allocation strategy of "technology + pharmaceuticals." Do not excessively chase semiconductor equipment, nor should short-term adjustments cause abandonment of the long-term potential of innovative drugs. Use tools like ETFs to diversify risk and dynamically adjust position ratios according to market changes.
Conclusion
The surge in semiconductor equipment ETF and the fall in innovative drug sector are microcosms of the current structural divergence in the A-share market. The former benefits from upward industry cycles, deepening domestic substitution, and policy support, while the latter faces multiple pressures such as medical insurance cost control, R&D uncertainty, and capital rotation. For investors, understanding the intrinsic logic and stage characteristics of different industries is more important than chasing short-term gains and losses. In the future, as the pace of global economic recovery becomes clearer and domestic policies continue to refine, both sectors are expected to usher in new development opportunities. But for now, embracing certainty, controlling risk, and maintaining patience are the keys to navigating the volatile market.
